Replies to post #153059 on Biotech Values

[DewDiligence]

I'm not sure they are as convenient to treat as treatment-naïve.

When GILD’s phase-3 HCV trials were designed, it wasn’t yet known whether IL28B status would have a bearing on SVR rates, so it made sense to define an interferon intolerant subgroup based on IL28B.

However, now that we know IL28B doesn’t matter in all-DAA regimens, the interferon intolerant classification is essentially obsolete as an entry criterion in all-DAA trials. From an investment standpoint, such patient populations can be considered the same as treatment-naïve, IMO.